Search

Justus B Cohen

from Allison Park, PA
Age ~71
Get Report
Also known as:
Justus Dr Cohen, Justus Bernard Cohen, Justus Gunhild Cohen
Phone and address:
2824 Shamrock Dr, Allison Park, PA 15101
(412) 487-5616
Related to:
Yannick D Cohen, 36Jeffrey J Cohen, 50Susan Rae Cohen, 75Amy Mayer, 44Paul S Cohen, 76Yaakov CohenAbbie Dorn, 48Arlan Cohen, 34
Connected to:
Abe A Cohen, 48Adrienne Cohen, 58Alana E Cohen, 44Alka V Cohen, 73Allan Cohen, 76Aly G Cohen, 51Amber S Cohen, 49Ami J Cohen, 60Amicah B Cohen, 65Amiram Cohen, 77

Justus Cohen Phones & Addresses

  • 2824 Shamrock Dr, Allison Park, PA 15101 (412) 487-5616
  • Cleveland, OH
  • Columbus, OH
  • San Francisco, CA
  • 2824 Shamrock Dr, Allison Park, PA 15101 (412) 225-4300

Work

Company: University of pittsburgh Position: Instructor

Education

Degree: PhD School / High School: Weizmann Institute of Science 1979 to 1983 Specialities: Molecular Genetics

Emails

j***[email protected]

Industries

Higher Education

Resumes

Resumes

Justus Cohen Photo 1

Instructor At University Of Pittsburgh

View page
Position:
Instructor at University of Pittsburgh
Location:
Greater Pittsburgh Area
Industry:
Higher Education
Work:
University of Pittsburgh
Instructor
Education:
Weizmann Institute of Science 1979 - 1983
PhD, Molecular Genetics

Publications

Us Patents

Identification Of Mutations In Herpes Simplex Virus Envelope Glycoproteins That Enable Or Enhance Vector Retargeting To Novel Non-Hsv Receptors

View page
US Patent:
20130096186, Apr 18, 2013
Filed:
Apr 18, 2011
Appl. No.:
13/641649
Inventors:
Hiroaki Uchida - Tokyo, JP
Justus B. Cohen - Allison Park PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh IL
International Classification:
C12N 15/869
US Classification:
514 44 R, 4353201, 435366
Abstract:
The invention provides modified HSV vectors that exhibit enhanced entry of cells, either through direct infection and/or lateral spread. In one aspect, HSV vectors of the present invention can directly infect cells through interaction with cell proteins other than typical mediators of HSV infection. In another aspect, the invention provides an HSV vector, which exhibits lateral spread in cells typically resistant to HSV lateral spread, such as cells lacking gD receptors. The invention further provides DNA encoding mutant forms of the HSV gB and gH glycoproteins, stocks of the inventive virus, and methods for effecting viral targeting and efficient entry of cells. The invention also pertains to the use of the inventive vectors for treating cancers.

Non-Toxic Hsv Vectors For Efficient Gene Delivery Applications And Complementing Cells For Their Production

View page
US Patent:
20220213508, Jul 7, 2022
Filed:
Mar 24, 2022
Appl. No.:
17/703762
Inventors:
- Pittsburgh PA, US
Justus Cohen - Allison Park PA, US
Yoshitaka Miyagawa - Pittsburgh PA, US
David Krisky - Sewickley PA, US
James Wechuck - Glenshaw PA, US
Darren Wolfe - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
C12N 15/86
A61K 35/763
A61K 48/00
C12N 7/00
Abstract:
Disclosed is a method for administering a transgene into a fibroblast in a subject comprising: a) providing a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein said recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide to be expressed in said fibroblast; and b) providing a pharmaceutically acceptable carrier; wherein said HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.

Oncolytic Hsv Vector

View page
US Patent:
20210138007, May 13, 2021
Filed:
Aug 5, 2020
Appl. No.:
16/985459
Inventors:
- Pittsburgh PA, US
Justus B. Cohen - Allison Park PA, US
Paola Grandi - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 35/763
C12N 7/00
C07K 14/005
Abstract:
The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

Antigenically Stealthed Oncolytic Viruses

View page
US Patent:
20210121513, Apr 29, 2021
Filed:
May 31, 2019
Appl. No.:
17/058379
Inventors:
- Pittsburgh PA, US
- Philadelphia PA, US
Doina Atanasiu - Norwood PA, US
Tina Marie Cairns - Warminster PA, US
Bonnie Lynn Hall - Allison Park PA, US
Justus B. Cohen - Allison Park PA, US
Ceren Tuzmen - Pittsburgh PA, US
International Classification:
A61K 35/763
C12N 7/00
Abstract:
Provided herein are antigenically stealthed HSV particles, and methods of use of the antigenically-stealthed HSV particles.

Trpv1 Modulatory Gene Product That Affects Trpv1-Specific Pain Behavioral Responses Identified In A Functional Screen Of An Hsv-Based Cdna Library

View page
US Patent:
20190292530, Sep 26, 2019
Filed:
Nov 21, 2018
Appl. No.:
16/198401
Inventors:
- Pittsburgh PA, US
Justus Bernard Cohen - Pittsburgh PA, US
Bonnie L. Reinhart - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
C12N 9/16
A61K 48/00
A61K 38/46
C07K 14/47
Abstract:
The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member 1 (TRPV1) by expressing PP1α in neurons. The invention also provides HSV vectors for expressing PP1α within neurons and compositions comprising such vectors.

Non-Toxic Hsv Vectors For Efficient Gene Delivery Applications And Complementing Cells For Their Production

View page
US Patent:
20190276845, Sep 12, 2019
Filed:
Nov 26, 2018
Appl. No.:
16/199715
Inventors:
- Pittsburgh PA, US
Justus Cohen - Pittsburgh PA, US
Yoshitaka Miyagawa - Pittsburgh PA, US
David Krisky - Sewickley PA, US
James Wechuck - Glenshaw PA, US
Darren Wolfe - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
C12N 15/86
A61K 48/00
C12N 7/00
A61K 35/763
Abstract:
In one embodiment, the invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector.

Oncolytic Hsv Vector

View page
US Patent:
20190262410, Aug 29, 2019
Filed:
Nov 14, 2018
Appl. No.:
16/191141
Inventors:
- Pittsburgh PA, US
Justus B. Cohen - Allison Park PA, US
Paola Grandi - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 35/763
C07K 14/005
C12N 7/00
Abstract:
The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.

Genome Editing Vectors

View page
US Patent:
20180148711, May 31, 2018
Filed:
May 27, 2016
Appl. No.:
15/575546
Inventors:
- South San Francisco CA, US
Kenneth P. GREENBERG - Berkeley CA, US
Justus B. COHEN - Allison Park PA, US
International Classification:
C12N 15/10
C12N 7/00
C12N 9/22
C12N 15/11
C12N 15/113
C12N 15/86
Abstract:
The present invention generally provides HSV-based genome editing vectors, cell-based compositions, and methods of using the same.
Control profile
Justus B Cohen from Allison Park, PA, age ~71 Get Report